Rigorous treatment of multispecies multimode ligand - Receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin

Journal of Chemical Information and Modeling

Volumn 51, Issue 5, 2011, Pages 1132-1150

  Natesan, Senthil ^a,b   Wang, Tiansheng ^b   Lukacova, Viera ^b   Bartus, Vladimir ^b   Khandelwal, Akash ^b   Balaz, Stefan ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; COMPUTATIONAL CHEMISTRY; IONIZATION; X RAYS;

AMYLOID FIBRIL FORMATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; LIGAND-RECEPTOR INTERACTIONS; PHYSIOLOGICAL CONDITION; QUANTITATIVE CHARACTERIZATION; RECEPTOR-LIGAND BINDING; STRUCTURAL INFORMATION; THERMODYNAMIC DESCRIPTION;

LIGANDS;

AMYLOID; LIGAND; PREALBUMIN; PROTEIN BINDING; THYROXINE; DRUG DERIVATIVE;

ALGORITHM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; COMPUTER PROGRAM; CONFORMATION; HUMAN; KINETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOISOMERISM; THERMODYNAMICS; ARTICLE; DRUG ANTAGONISM; PROTEIN BINDING;

ALGORITHMS; AMYLOID; BINDING SITES; HUMANS; KINETICS; LIGANDS; MOLECULAR CONFORMATION; PREALBUMIN; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; STEREOISOMERISM; THERMODYNAMICS; THYROXINE;

EID: 79960266136     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200055s     Document Type: Article

References (93)

1. Hilal, S. H.; Bornander, L. L.; Carreira, L. A. Hydration equilibrium constants of aldehydes, ketones and quinazolines. QSAR Comb. Sci. 2005, 24, 631-637.
2. Davies, N. M. Chiral inversion. Chirality Drug Des. Dev. 2004, 351-392.
3. Mattos, C. Ringe, D. Multiple binding modes. In 3D QSAR in DrugDesign: Theory, Methods, and Applications; Kubinyi, H., Ed.; Escom: Leiden, the Netherlands, 1993, 226 - 254.
4. Case, D. A.; Karplus, M. Dynamics of ligand binding to heme protein. J. Mol. Biol. 1979, 132, 343-368.
5. Nelson, R. D.; Gottlieb, D. I.; Balasubramanian, T. M.; Marshall, G. R. Opioid peptides: analysis of specificity and multiple binding modes through computer-aided drug design and structure-activity studies. NIDA Res. Monogr. 1986, 69 204-230. (Pubitemid 17201096)
6. Dean, P. M. Molecular similarity. In 3D QSAR in Drug Design: Theory, Methods, and Applications; Kubinyi, H., Ed.; Escom: Leiden, the Netherlands, 1993, 150 - 172.
7. Martin, Y. C.; Hackbarth, J. J. Theoretical model-based equations for the linear free energy relationships of the biological activity of ionizable substances. 1. Equilibrium-controlled potency. J. Med. Chem. 1976, 19 1033-1039.
8. Kubinyi, H. Opinion: Drug research: myths, hype and reality. Nat. Rev. Drug Discovery 2003, 2, 665-668. (Pubitemid 37368830)
9. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; and Dunn, D. A. The conformational parameter in drug design: The active analog approach. In Computer-Assisted Drug Design; Olson, E. C., Christoffersen, R. E., Eds.; ACS: Washington, DC, 1979; pp 205 - 226.
10. Crippen, G. M. Distance geometry approach to rationalizing binding data. J. Med. Chem. 1979, 22, 988-997. (Pubitemid 10235938)
11. Crippen, G. M. Quantitative structure-activity relationships by distance geometry: Systematic analysis of dihydrofolate reductase inhibitors. J. Med. Chem. 1980, 23, 599-606. (Pubitemid 11237813)
12. Crippen, G. M. Quantitative structure - activity relationships by distance geometry: Thyroxine binding site. J. Med. Chem. 1981, 24, 198-203. (Pubitemid 11183411)
13. Ghose, A. K.; Crippen, G. M. Quantitative structure - activity relationship by distance geometry: Quinazolines as dihydrofolate reductase inhibitors. J. Med. Chem. 1982, 25, 892-899. (Pubitemid 13231853)
14. Boulu, L. G.; Crippen, G. M. Voronoi binding site models: Calculation of binding modes and influence of drug binding data accuracy. J. Comput. Chem. 1989, 10 673-682.
15. Ciubotariu, D.; Deretey, E.; Oprea, T. I.; Sulea, T.; Simon, Z.; Kurunczi, L.; Chiriac, A. Multiconformational Minimal Steric Difference. Structure-acetylcholinesterase hydrolysis rates relations for acetic acid esters. Quant. Struct. Act. Relat. 1993, 12, 367-372. (Pubitemid 24034198)
16. Sulea, T.; Kurunczi, L.; Simon, Z. Dioxin-type activity for polyhalogenated arylic derivatives: A QSAR model based on MTD-method. SAR QSAR Environ. Sci. 1995, 3, 37-61.
17. Sulea, T.; Kurunczi, L.; Oprea, T. I.; Simon, Z. MTD-ADJ: A multiconformational minimal topologic difference for determining bioactive conformers using adjusted biological activities. J. Comput.-Aided Mol. Des. 1998, 12, 133-146. (Pubitemid 128691447)
18. Cramer, R. D. I.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110 5959-5967.
19. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146. (Pubitemid 24379702)
20. Kim, K. H.; Martin, Y. C. Direct prediction of linear free energy substituent effects from 3D structures using comparative molecular field analysis. 1. Electronic effects of substituted benzoic acids. J. Org. Chem. 1991, 56, 2723-2729.
21. Nicklaus, M. C.; Milne, G. W.; Burke-TR, J. QSAR of conformationally flexible molecules: Comparative molecular field analysis of protein-tyrosine kinase inhibitors. J. Comput.-Aid. Mol. Des. 1992, 6 487-504.
22. Cramer, R. D. I. Wold, S. B. Compartive Molecular Field Analysis (CoMFA). U.S. Patent 5,307,287 1994.
23. Lukacova, V.; Balaz, S. Multimode ligand binding in receptor site modeling: Implementation in CoMFA. J. Chem. Inf. Comp. Sci. 2003, 43 2093-2105.
24. Hopfinger, A. J.; Burke, B. J.; Dunn, W. J. I. A generalized formalism of three-dimensional quantitative structure-property relationship analysis for flexible molecules using tensor representation. J. Med. Chem. 1994, 37 3768-3774. (Pubitemid 24346761)
25. Burke, B. J.; Dunn, W. J.; Hopfinger, A. J. Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors. J. Med. Chem. 1994, 37 3775-3788. (Pubitemid 24346762)
26. Dunn, W. J.; Hopfinger, A J.; Catana, C.; Duraiswami, C. Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure - activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis. J. Med. Chem. 1996, 39 4825-4832.
27. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B. Q.; Albuquerque, M.; Madhav, P. J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc. 1997, 119 10509-10524. (Pubitemid 27487990)
28. Albuquerque, M. G.; Hopfinger, A. J.; Barreiro, E. J.; deAlencastro, R. B. Four-dimensional quantitative structure - activity relationship analysis of a series of interphenylene 7-oxabicycloheptane oxazole thromboxane A(2) receptor antagonists. J. Chem. Inf. Comput. Sci. 1998, 38 925-938. (Pubitemid 128611010)
29. Hopfinger, A. J.; Reaka, A.; Venkatarangan, P.; Duca, J. S.; Wang, S. Construction of a virtual high throughput screen by 4D-QSAR analysis: Application to a combinatorial library of glucose inhibitors of glycogen phosphorylase b. J. Chem. Inf. Comput. Sci. 1999, 39 1151-1160. (Pubitemid 129579851)
30. Venkatarangan, P.; Hopfinger, A. J. Prediction of ligand-receptor binding free energy by 4D-QSAR analysis: Application to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Comput. Sci. 1999, 39 1141-1150. (Pubitemid 129579850)
31. Liu, J.; Pan, D.; Tseng, Y.; Hopfinger, A. J. 4D-QSAR analysis of a series of antifungal P450 inhibitors and 3D-pharmacophore comparisons as a function of alignment. J. Chem. Inf. Comput. Sci. 2003, 43, 2170-2179.
32. Pan, D.; Liu, J.; Senese, C.; Hopfinger, A. J.; Tseng, Y. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure - activity relationship analysis. J. Med. Chem. 2004, 47, 3075-3088. (Pubitemid 38702703)
33. Marshall, G. R. Molecular modeling in drug design. In Burger's Medicinal Chemistry; Wolff, M. E., Ed.; John Wiley & Sons: New York, 1995; pp 573 - 659.
34. Lewi, P. J.; de Jonge, M.; Daeyaert, F.; Koymans, L.; Vinkers, M.; Heeres, J.; Janssen, P. A. J.; Arnold, E.; Das, K.; Clark, A. D., Jr; Hughes, S. H.; Boyer, P. B.; de Bethune, M. P.; Pauwels, R.; Andries, K.; Kukla, M.; Ludovici, D.; de Corte, B.; Kavash, R.; Ho, C. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J. Comput.-Aid. Mol. Des. 2003, 17 129-134. (Pubitemid 37062776)
35. Balaz, S.; Hornak, V.; Haluska, L. Receptor mapping with multiple binding modes: Binding site of PCB-degrading dioxygenase. Chemometr. Intell. Lab. 1994, 24, 185-191. (Pubitemid 24251833)
36. Hornak, V.; Balaz, S.; Schaper, K. J.; Seydel, J. K. Multiple binding modes in 3D-QSAR: Microbial degradation of polychlorinated biphenyls. Quant. Struct. Act. Relat. 1998, 17 427-436. (Pubitemid 28532541)
37. Vedani, A.; McMasters, D. R.; Dobler, M. Multi-conformational ligand representation in 4D-QSAR: Reducing the bias associated with ligand alignment. Quant. Struct. Act. Relat. 2000, 19 149-161. (Pubitemid 30240803)
38. Aqvist, J.; Medina, C.; Samuelsson, J. E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994, 7, 385-391. (Pubitemid 24063137)
39. Carlson, H. A.; Jorgensen, W. L. An extended linear response method for determining free energies of hydration. J. Phys. Chem. 1995, 99 10667-10673.
40. Khandelwal, A.; Lukacova, V.; Kroll, D. M.; Comez., D.; Raha, S.; Balaz, S. Simulation-based predictions of binding affinities of matrix metalloproteinase inhibitors. QSARComb. Sci. 2004, 23, 754-766. (Pubitemid 39578077)
41. Head, R. D.; Smythe, M. L.; Oprea, T. I.; Waller, C. L.; Green, S. M.; Marshall, G. R. VALIDATE: A newmethod for the receptor-based prediction of binding affinities of novel ligands. J. Am. Chem. Soc. 1996, 118 3959-3969. (Pubitemid 26168541)
42. Tokarski, J. S.; Hopfinger, A. J. Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: Application to a set of peptidometic renin inhibitors. J. Chem. Inf. Comput. Sci. 1997, 37 792-811. (Pubitemid 127603594)
43. Venkatarangan, P.; Hopfinger, A. J. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: Applications to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Med. Chem. 1999, 42, 2169-2179. (Pubitemid 29284236)
44. Ortiz, A. R.; Pisabarro, M. T.; Gago, F.; Wade, R. C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem. 1995, 38 2681-2691.
45. Huang, D.; Caflisch, A. Efficient evaluation of binding free energy using continuum electrostatics solvation. J. Med. Chem. 2004, 47 5791-5797. (Pubitemid 39447274)
46. Lill, M. A.; Vedani, A.; Dobler, M. Raptor: Combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: Application toward the simulation of structurally diverse ligand sets. J. Med. Chem. 2004, 47, 6174-6186. (Pubitemid 39587242)
47. Lill, M. A.; Dobler, M.; Vedani, A. In silico prediction of receptor-mediated environmental toxic phenomena - application to endocrine disruption. SAR. QSAR. Environ. Res. 2005, 16 149-169. (Pubitemid 40623247)
48. Lill, M. A.; Winiger, F.; Vedani, A.; Ernst, B. Impact of induced fit on ligand binding to the androgen receptor: A multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem. 2005, 48 5666-5674. (Pubitemid 41298341)
49. Lill, M. A.; Dobler, M.; Vedani, A. Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR. ChemMedChem 2006, 1 73-81. (Pubitemid 44104980)
50. Khandelwal, A.; Lukacova, V.; Comez, D.; Kroll, D. M.; Raha, S.; Balaz, S. A combination of docking, QM/MM Methods, and MD simulation for binding affinity estimation of metalloprotein ligands. J. Med. Chem. 2005, 48 5437-5447. (Pubitemid 41209242)
51. Khandelwal, A.; Balaz, S. QM/MM linear response method distinguishes ligand affinities for closely related metalloproteins. Proteins: Struct, Funct., Bioinf. 2007, 69 326-339. (Pubitemid 47429294)
52. Colon, W.; Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31 8654-8660.
53. Uemichi, T.; Murrell, J. R.; Zeldenrust, S.; Benson, M. D. Anew mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy. J. Med. Genet. 1992, 29, 888-891. (Pubitemid 23035214)
54. Baures, P. W.; Oza, V. B.; Peterson, S. A.; Kelly, J. W. Syntesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflamatory drug, flufenamic acid. Bioorg. Med. Chem. 1999, 7, 1339-1347. (Pubitemid 29292374)
55. Oza, V. B.; Petrassi, H. M.; Purkey, H. E.; Kelly, J. W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1-6. (Pubitemid 29023287)
56. Andrea, T. A.; Cavalieri, R. R.; Goldfine, I. D.; Jorgensen, E. C. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19 55-63. (Pubitemid 10154185)
57. De La Paz, P.; Burridge, J. M.; Oatley, S. J.; Blake, C C. F. Multiple modes of binding of thyroid hormones and other iodothyr-onines to human plasma transthyretin. In The Design of Drugs to Macromolecular Targets.; Beddell, C. R., Ed.; John Wiley and Sons: Chichester, U.K., 1992, 119 - 172.
58. Nilsson, S. F.; Peterson, P. A. Evidence for multiple thyrox-ine-binding sites in human prealbumin. J. Biol. Chem. 1971, 246, 6098-6105.
59. Hilal, S. H.; Karickhoff S. W.; Carreira, L. A. Estimation of microscopic, zwitterionic ionization constants, isoelectric point and molecular speciation of organic compounds. Talanta 1999, 50, 827-840.
60. Wojtczak, A.; Cody, V.; Luft, J. R.; Pangborn, W. Structures of human transthyretin complexed with thyroxine at 2.0 angstrom resolution and 3',5' dinitron acetyl L thyronine at 2.2 angstrom resolution. Acta Crystallogr. D. 1996, 52 (Part 4), 758-765.
61. Neumann, P.; Cody, V.; Wojtczak, A. Ligand binding at the transthyretin dimer-dimer interface: Structure of the transthyretin-T4Ac complex at 2.2 anstrom resolution. Acta Crystallogr. D. 2005, D61 1313-1319. (Pubitemid 43943129)
62. Wojtczak, A.; Luft, J.; Cody, V. Mechanism of molecular recognition. Structural aspects of 3,3'- diiodo-L-thyronine binding to human serum transthyretin. J. Biol. Chem. 1992, 267, 353-357.
63. Sybyl 8.1; Tripos Inc.: St. Louis, Missouri, 2009.
64. Jaguar; Schrödinger LLC: Portland, OR, 2003.
65. Blaney, J. M.; Jorgensen, E. C.; Connolly, M. L.; Ferrin, T. E.; Langridge, R.; Oatley, S. J.; Burridge, J. M.; Blake, C. C. Computer graphics in drug design: Molecular modeling of thyroid hormone-prealbumin interactions. J. Med. Chem. 1982, 25, 785-790. (Pubitemid 12056955)
66. Blaney, J. M.; Weiner, P. K.; Dearing, A.; Kollman, P. A.; Jorgensen, E. C.; Oatley, S. J.; Burridge, J. M.; Blake, C. C. F. Molecular mechanics simulation of protein-ligand interactions: Binding of thyroid hormone analogues to prealbumin. J. Am. Chem. Soc. 1982, 104 6424-6434. (Pubitemid 13182931)
67. Somack, R.; Andrea, T. A.; Jorgensen, E. C. Thyroid hormone binding to human serum prealbumin and rat liver nuclear receptor: Kinetics, contribution of the hormone phenolic hydroxyl group, and accommodation of hormone side-chain bulk. Biochemistry 1982, 21 163-170. (Pubitemid 12141664)
68. Pitt-Rivers, R.; Stanbury, J. B.; Rapp, B. Conversion of thyroxine to 3-5-3'-triiodothyronine in vivo. J. Clin. Endocr. Metab. 1955, 15, 616-620.
69. Baxter, J. D.; Eberhardt, N. L.; Apriletti, J. W.; Johnson, L. K.; Ivarie, R. D.; Morris, J. A.; Seeburg, P. H.; Goodman, H. M. Thyroid hormone receptors and responses. Recent Prog. Horm. Res. 1979, 35, 97-153. (Pubitemid 10244046)
70. Cody, V. Role of iodine in thyroid hormones: molecular conformation of a halogen-free hormone analogue. J. Med. Chem. 1980, 23, 584-587.
71. Bartalena, L.; Robbins, J. Thyroid hormone transport proteins. Clin. Lab. Med. 1993, 13 583-598. (Pubitemid 23267628)
72. Kanda, Y.; Goodman, D. S.; Canfield, R. E.; Morgan, F. J. Amino acid sequence of human plasma prealbumin. J. Biol. Chem. 1974, 249, 6796-6805.
73. Balke, C. C. F.; Swan, I. D. A.; Rerat, C.; Berthou, J.; Laurent, A.; Rerat, B. X-ray study of the subunit structure of prealbumin. J. Mol. Biol. 1971, 61 217-224.
74. Cheng, S. Y.; Pages, R. A.; Saroff, H. A.; Edelhoch, H.; Robbins, J. Analysis of thyroid hormone binding to human serum prealbumin by 8-anilinonaphthalene-1-sulfonate fluorescence. Biochemistry 1977, 16 3707-3713. (Pubitemid 8162704)
75. Cheng, S. Y.; Wilchek, M.; Cahnmann, H. J.; Robbins, J. Affinity labeling of human serum prealbumin with N-bromoacetyl-L-thyroxine. J. Biol. Chem. 1977, 252, 6076-6081. (Pubitemid 8192561)
76. Ferguson, R. N.; Edelhoch, H.; Saroff, H. A.; Robbins, J.; Cahnmann, H. J. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry 1975, 14, 282-289.
77. Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. P. Natl. Acad. Sci. U.S.A. 1996, 93 15051-15056. (Pubitemid 27009550)
78. Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, F. W.; Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7, 312-320.
79. Petrassi, H. M.; Klabunde, T.; Sacchettini, J.; Kelly, J. W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 2000, 122, 2178-2192. (Pubitemid 30164628)
80. Green, N. S.; Foss, T. R.; Kelly, J. W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. P. Natl. Acad. Sci. USA 2005, 102, 14545-14550. (Pubitemid 41457094)
81. Wojtczak, A.; Neumann, P.; Cody, V. Structure of a new polymorphic monoclinic form of human transthyretin at 3 Å resolution reveals a mixed complex between unliganded and T4-bound tetramers of TTR. Acta Crystallogr. D. 2001, D57, 957-967. (Pubitemid 32620886)
82. Wojtczak, A.; Luft, J.; Cody, V. Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-L-thyronine binding to human serum transthyretin. J. Biol. Chem. 1992, 267, 353-357.
83. Wojtczak, A.; Cody, V.; Luft, J. R.; Pangborn, W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr. D 1996, 52, 758-765.
84. Clare, B. W. QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens. J. Comput.-Aid. Mol. Des. 2002, 16 611-633. (Pubitemid 36204615)
85. Supuran, C T.; Clare, B. W. Quantum theoretic QSAR of benzene derivatives: Some enzyme inhibitors. J. Enzyme Inhib. Med. Chem. 2004, 19 237-248. (Pubitemid 39004277)
86. Clare, B. W.; Supuran, C. T. A physically interpretable quantum-theoretic QSAR for some carbonic anhydrase inhibitors with diverse aromatic rings, obtained by a new QSAR procedure. Bioorgan. Med. Chem. 2005, 13 2197-2211. (Pubitemid 40261139)
87. Clare, B. W.; Supuran, C. T. Predictive flip regression: A technique for QSAR of derivatives of symmetric molecules. J. Chem. Inf. Model 2005, 45, 1385-1391. (Pubitemid 41476021)
88. Perola, E.; Charifson, P. S. Conformational analysis of drug-like molecules bound to proteins: An extensive study of ligand reorganization upon binding. J. Med. Chem. 2004, 47, 2499-2510. (Pubitemid 38580088)
89. Wang, J.; Szewczuk, Z.; Yue, S. Y.; Tsuda, Y.; Konishi, Y.; Purisima, E. O. Calculation of relative binding free energies and configurational entropies: A structural and thermodynamic analysis of the nature of non-polar binding of thrombin inhibitors based on hirudin 55-65. J. Mol. Biol. 1995, 253, 473-492.
90. Jullien, L.; Proust, A.; LeMenn, J. C. How does the Gibbs free energy evolve in a system undergoing coupled competitive reactions? J. Chem. Educ. 1998 75, 194-199. (Pubitemid 128591180)
91. Smith, W. R. Missen, R. W. Chemical Reaction Equilibrium Analysis: Theory and Algorithms. New York: John Wiley and Sons, 1982; pp 1 - 364.
92. Parker, M. H.; Lunney, E. A.; Ortwine, D. F.; Pavlovsky, A. G.; Humblet, C.; Brouillette, C. G. Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metallo-proteinase-3) catalytic domain by isothermal titration calorimetry. Biochemistry 1999, 38 13592-13601.
93. Venkatasubban, K. S.; Schowen, R. L. The proton inventory technique. CRC Crit. Rev. Biochem. Mol. 1984, 17 1-44.